araag2/HINT huggingface dataset:
Clinical trial NCT00327171 (phase 2, status: completed)
Conditions: neoplasms, cancer of the ovary
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®), aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrap®)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Participants who met the following criteria were eligible for the study.

        Inclusion Criteria:

          -  Histologically-confirmed ovarian epithelial (including fallopian tube and primary
             peritoneal) adenocarcinoma.

          -  Prior treatment with at least 2 treatment regimens in the advanced disease treatment
             setting

          -  Platinum-resistant disease defined by relapse or progression of disease during or
             after treatment, or drug intolerance

          -  Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or
             progression of disease during or after treatment, or drug intolerance

          -  Evidence of at least one unidimensional measurable tumor lesion by computed tomography
             (CT) or magnetic resonance imaging (MRI) scan according to Response Evaluation
             Criteria in Solid Tumors (RECIST) that has not been treated with surgery or radiation
             therapy

        Exclusion Criteria:

          -  Diagnosis of any second malignancy within the last 5 years, except for adequately
             treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the
             cervix uteri

          -  Prior treatment with a vascular endothelial growth factor (VEGF) or VEGF receptor
             inhibitor

          -  More than 3 chemotherapy regimens in the advanced disease treatment setting

          -  Uncontrolled hypertension

        The above information is not intended to contain all considerations relevant to potential
        participation in a clinical trial.
Clinical trial NCT01379144 (phase 2, status: completed)
Conditions: primary open angle glaucoma, ocular hypertension
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111, H40.053, H40.051, H40.052, H40.059
Drugs: latanoprost 75 ug, latanoprost 100 ug, latanoprost 125 ug, latanoprost 50 ug
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 years of age or older.

          -  Primary open angle glaucoma (POAG) or ocular hypertension (OHT) requiring unilateral
             or bilateral administration of intraocular pressure (IOP) lowering treatment,
             including patients who were naïve to IOP lowering treatment.

          -  IOP between ≥ 24 mmHg and ≤ 36 mmHg in at least one eye at the 8 AM time point at
             baseline/randomization.

        Exclusion Criteria:

          -  Closed/barely open anterior chamber angle or a history of acute angle closure.

          -  A history of discontinued prostaglandin IOP lowering treatment, unless the reason for
             discontinuation was participation in a clinical study.

          -  Ocular surgery or argon laser trabeculoplasty in one or both eyes within 3 months
             prior to the screening visit.

          -  Use or anticipated requirement during the study of any topical medication that was
             known to affect IOP.

          -  Anticipated need to modify systemic medication known to affect IOP (eg,
             beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel blockers,
             angiotension converting enzyme inhibitors, and angiotension II receptor antagonists)
             during the study period.
Clinical trial NCT00135408 (phase 2, status: completed)
Conditions: malignant melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10
Drugs: ipilimumab+ placebo, ipilimumab+ budesonide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of unresectable Stage III or IV malignant melanoma
             (excluding ocular melanoma)

          -  Flexible Sigmoidoscopy and colonic biopsy required

        Exclusion Criteria:

          -  Patients with active, untreated central nervous system metastasis. Patients with
             autoimmune disease.
Clinical trial NCT01461941 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: e6005, e6005 ointment (vehicle)
SMILES: CNC1=NC(C2=CC=CC(NC(=O)C3=CC=C(C=C3)C(=O)OC)=C2)=C2C=C(OC)C(OC)=CC2=N1
Eligibility criteria:

        Inclusion Criteria

          -  Adults of both genders aged 20 to 64 years at the time when the written informed
             consent is obtained.

          -  Outpatients diagnosed with atopic dermatitis.

        Exclusion Criteria

          -  Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum
             contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen
             disorder or Netherton's syndrome, etc., which could have an effect on the pathological
             evaluation of the atopic dermatitis.

          -  Patients with active infection that requires oral or intravenous administration of
             antibiotics, antifungal or antivirus agent/s at baseline.

          -  Patients with advanced disease or abnormal laboratory tests that would possibly affect
             the safety of the subject or the implementation of this study.
Clinical trial NCT00468169 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cetuximab, 5-fu, hydroxyurea, cisplatin
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC(=O)NO, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 or older

          -  Stage III and IV head and neck cancer

          -  Patients with squamous cell carcinoma of unknown primary and suspected origin in the
             head and neck area

          -  No prior chemotherapy or radiotherapy

          -  Prior surgical therapy of incisional or excisional biopsy and organ-sparing procedures
             only

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          -  Normal organ and marrow function

        Exclusion Criteria:

          -  Unequivocal demonstration of metastatic disease

          -  Known severe hypersensitivity to drugs used in the study

          -  Treatment with a non-approved or investigational drug within 30 days before Day 1

          -  Incomplete healing from previous surgery

          -  Pregnancy or breast feeding

          -  Uncontrolled intercurrent illness including

          -  Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any
             history of clinically significant CHF

          -  Acute hepatitis or known HIV

          -  Severe baseline neurologic deficits

          -  Prior therapy which specifically and directly targets the EGFR pathway

          -  Prior severe infusion reaction to a monoclonal antibody
Clinical trial NCT00557401 (phase 2, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: xp19986 sr3, 20 mg qd, xp19986 sr3, 40 mg qd, xp19986 sr3, 60 mg qd, xp19986 sr3, 30 mg bid, placebo
SMILES: CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C, CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C, CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C, CC(C)[C@H](OC(=O)NC[C@H](CC(O)=O)C1=CC=C(Cl)C=C1)OC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History and documentation of GERD diagnosed by a gastroenterologist, with symptoms
             (heartburn and/or regurgitation) on ≥ 3 days during the week prior to screening and
             prior to randomization

        Exclusion Criteria:

          -  Current or historical endoscopic evidence of erosive esophagitis LA Classification
             Grade B, C, or D
Clinical trial NCT00365560 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: tiotropium, placebo
SMILES: [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Outpatients of either sex, age 18 - 75 years, with at least a documented 5 year history of
        asthma, and a current diagnosis of severe, persistent asthma (GINA step 4), smoking history
        < 10 pack years and >= 1 year smoking cessation; Patients must be symptomatic

        Exclusion Criteria:

        Patients

          -  with a recent history (i.e., six months or less) of myocardial infarction,

          -  who have been hospitalized for heart failure (NYHA class III or IV) within the past
             year,

          -  with any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia
             requiring intervention or a change in drug therapy within the past year,

          -  with malignancy for which the patient has undergone resection, radiation ther apy or
             chemotherapy within the last five years,

          -  who have undergone thoracotomy with pulmonary resection,

          -  with moderate to severe renal impairment (creatinine clearance = 50 mL/min)
Clinical trial NCT01482884 (phase 2, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: tralokinumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed ulcerative colitis at least 90 days prior randomisation.

          -  Men or women age 18 - 75 years.

          -  Non-hospitalized patients with moderate-severe ulcerative colitis treated with stable
             background UC therapy (e.g. containing 5-aminosalicylates, and/or low dose of
             glucocorticosteroids, and/or purine analogue) prior to randomization.

          -  Females of childbearing potential who are sexually active with a nonsterilized male
             partner must use highly effective contraception from Day1.

          -  Nonsterilized males or sterilized males who are ≤1 year post-vasectomy who are
             sexually active with a female partner of childbearing potential must use a highly
             effective method of contraception.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women.

          -  History of colostomy.

          -  Current diagnosis of indeterminate colitis, Crohn's disease, ischemic colitis,
             fulminant colitis and/or toxic megacolon and patients with ulcerative colitis limited
             to the rectum (ulcerative proctitis).

          -  Hepatitis B, C or HIV.

          -  History of cancer.
Clinical trial NCT00641979 (phase 2, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: budesonide, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  In the opinion of the investigator, is a candidate for treatment with nasal steroids
             based on a history of either a) inadequate control of symptoms with antihistamines,
             decongestants and/or immunotherapy, or b) prior successful treatment with nasal
             steroids.

          -  A documented history of at least one year of seasonal allergic rhinitis.

          -  A positive response to a skin prick test for grass allergens that must be present in
             the subject's environment throughout the study.

        Exclusion Criteria:

          -  Primary or secondary adrenal insufficiency

          -  Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza,
             upper respiratory tract infection or structural abnormalities of the nose (e.g.,
             septal deviation, nasal polyps) symptomatic enough to cause significant nasal
             obstruction as judged by the investigator.

          -  A diagnosis of asthma requiring treatment as specified in the protocol.
Clinical trial NCT01224145 (phase 2, status: completed)
Conditions: hernia, postoperative pain
ICD codes: Q40.1, Q79.0, K42.1, K43.1, K43.4, K44.1, Q79.51
Drugs: 5x5cm bupivacaine collagen sponges
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Man ≥18 years

          2. Has a planned unilateral inguinal herniorrhaphy (laparoscopy, transabdominal
             preperitoneal [TAPP] approach or totally extraperitoneal [TEP] approach) or
             laparoscopic umbilical herniorrhaphy to be performed according to standard surgical
             technique under general anesthesia.

          3. Willing to use opioid rescue analgesia.

        Exclusion Criteria:

          1. Has a known hypersensitivity to amide local anesthetics, opioids, or bovine products.

          2. Scheduled for bilateral inguinal herniorrhaphy.

          3. Undergone a prior herniorrhaphy at the location scheduled for repair.

          4. Undergone major surgery within 3 months of the scheduled herniorrhaphy.
Clinical trial NCT00392704 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: bevacizumab, erlotinib, paclitaxel, 5-fu
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically confirmed head & neck cancer

          -  Considered low cure rate with local therapy

          -  No prior treatment for this cancer

          -  Able to be up & about and perform self care

          -  Adequate renal and liver function

          -  Must be 18 years of age or older

          -  All patients will need an indwelling central venous access catheter

          -  Must be able to give written informed consent

        Exclusion Criteria:

          -  Active cancer treatment in the last 5 years

          -  Pregnant or lactating women

          -  History of stroke, transient ischemic attacks, or acute myocardial infarction within
             the past 6 months or any other serious cardiovascular disease

          -  History of neurological disease

          -  Recent history of blood in the sputum or vomitus

          -  Non-healing wounds, ulcer or long bone fractures

          -  History of bleeding problems or coagulation problems

          -  History of abdominal fistula, gastrointestinal perforation or intrabdominal abscess
             within 6 months

          -  History of uncontrolled hypertension

          -  Symptomatic peripheral vascular disease

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have. You can then decide if you wish to
        participate.
Clinical trial NCT00262860 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: bortezomib, gemcitabine hydrochloride
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed Hodgkin's lymphoma

               -  Recurrent or refractory disease after prior standard combination chemotherapy

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion > 1 cm by
             physical exam or imaging studies

          -  No history of non-Hodgkin's lymphoma

          -  No history of other hematological malignancy

        PATIENT CHARACTERISTICS:

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Platelet count ≥ 100,000/mm^3

          -  Absolute neutrophil count ≥ 1,000/mm^3

        Hepatic

          -  Bilirubin ≤ 2 times upper limit of normal (ULN) (unless due to Gilbert's disease or
             involvement by Hodgkin's lymphoma)

          -  AST ≤ 3 times ULN (unless due to involvement by Hodgkin's lymphoma)

        Renal

          -  Creatinine clearance ≥ 30 mL/min

        Cardiovascular

          -  Ejection fraction ≥ 40% by MUGA or echocardiogram (in patients with a history of
             cardiac disease)

        Pulmonary

          -  Must not require supplemental oxygen therapy

        Immunologic

          -  No known HIV infection

          -  No uncontrolled bacterial, viral, or fungal infection

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy requiring therapy

          -  No peripheral neuropathy ≥ grade 2 within the past 14 days

          -  No hypersensitivity to boron

          -  No hypersensitivity to mannitol

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 30 days since prior monoclonal antibody therapy for Hodgkin's lymphoma

          -  More than 6 months since prior autologous stem cell transplantation

          -  No prior allogeneic stem cell transplantation

          -  No concurrent sargramostim (GM-CSF)

          -  No concurrent pegfilgrastim or filgrastim (G-CSF)

          -  No concurrent interleukin-11(oprelvekin)

        Chemotherapy

          -  See Disease Characteristics

          -  More than 30 days since prior chemotherapy for Hodgkin's lymphoma

          -  No prior treatment with gemcitabine hydrochloride

        Endocrine therapy

          -  More than 30 days since prior corticosteroid therapy for Hodgkin's lymphoma

          -  No concurrent corticosteroid therapy

        Radiotherapy

          -  More than 30 days since prior radiotherapy for Hodgkin's lymphoma

        Other

          -  No prior treatment with bortezomib

          -  More than 14 days since prior investigational drugs

          -  No other concurrent investigational agents
Clinical trial NCT00837200 (phase 2, status: terminated)
Conditions: non-hodgkins lymphoma, hodgkins lymphoma, multiple myeloma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C90.01, C90.02, C90.00
Drugs: oncaspar, doxil, decadron
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    pi said to close accrual do to funding
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented lymphoid malignancies, regardless of their origin (B,T or
             NK). These include ALL, CLL, HL, NHL, MM and PCL.

          -  Patients must have failed at least one standard regimen of chemotherapy for their
             illness. They may have had unlimited prior regimens.

          -  Performance status of ≤ 2 as per ECOG scale.

          -  ALT < 2.5 times the upper limit of normal

          -  Anticipated life expectancy of at least 12 weeks

          -  Patients will be allowed to have baseline cytopenias, but ANC should be >200/μl and a
             platelet count > 25,000/ μl (within 2 weeks of starting therapy).

          -  Patients must have a serum creatinine level ≤ 2 mg/dL (within 2 weeks of starting
             therapy).

          -  Male or female adults of at least 18 years of age.

          -  Signed written informed consent and willingness to meet follow-up schedule and study
             procedure obligations

          -  Left Ventricular Ejection Fraction (LVEF) > 40% by echocardiogram or MUGA scan
             performed within 60 days prior to registration

          -  Women and men of childbearing potential must agree to employ adequate contraception to
             prevent pregnancy while on therapy.

        Exclusion Criteria:

          -  Chemotherapy or radiotherapy received within the previous 2 weeks.

          -  Uncontrolled, active infection requiring IV antibiotics.

          -  Psychiatric illness that could potentially interfere with the completion of treatment
             according to this protocol.

          -  Pregnant or potential for pregnancy.

          -  Breast-feeding.

          -  Prior asparaginase therapy complicated by pancreatitis, allergic reaction, hemorrhagic
             event, or thrombosis

          -  Previous treatment with pegylated asparaginase

          -  Prior doxorubicin exposure, more than 400 mg/m2

          -  Clinically significant CHF

          -  No prior malignancy is allowed except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
             been disease free for at least three years. Prior malignancy is acceptable provided
             there has been no evidence of disease within the three year interval.